RxDoctor Payments Data

Royce Darbonne, MD

Family Medicine · Opelousas, LANPI 1730767278

Payments from drug & device makers

$1,276in general payments, 2019–2025

Across 57 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$146
  • Amgen$144
  • AstraZeneca$139
  • GSK$131
  • Boehringer Ingelheim$96
  • Novo Nordisk$87
  • plus $533 from 18 others

What the payments were for

  • Food & beverage$1,276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,276 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,954
Medicare patients
96
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab13$36,199
OzempicSemaglutide26$26,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,769
InvokanaCanagliflozin14$16,096
JardianceEmpagliflozin16$11,959
EliquisApixaban19$10,475
Albuterol Sulfate HfaAlbuterol Sulfate18$603
Atorvastatin Calcium35$525
Fluticasone Propionate17$344
Tamsulosin Hcl21$326
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$300
Nifedipine ErNifedipine12$235
Pantoprazole Sodium32$230
Albuterol Sulfate11$213
Metoprolol Succinate35$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$26,41526 claims
GSKTrelegy Ellipta$131$20,76926 claims
Boehringer IngelheimJardiance$96$11,95916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →